WebTherapeutics. Headquarters Regions Asia-Pacific (APAC) Founded Date 2024. Founders Alan Au. Operating Status Active. Last Funding Type Venture - Series Unknown. Company Type For Profit. GT Apeiron Therapeutics is a developer of innovative drugs utilizing artificial intelligence technology. The company develops breakthrough investigational ... WebFeb 13, 2024 · DIGESTOME THERAPEUTICS, INC branch. Company Number 4566652 Previous Company Numbers. C4566652; Status Active Incorporation Date 13 February 2024 (almost 3 years ago) Company Type Stock Corporation - Out of State - Stock Jurisdiction California (US) Branch Branch of DIGESTOME THERAPEUTICS, INC.
Zhongze Therapeutics announces exclusive license of DGX-001 …
WebZHONGZE Therapeutics is a clinical stage company committed to discovering innovative medicines that will contribute to a world without suffering from schizophrenia. R&D. ... Congratulations to Our Partner Digestome Therapeutics for completing the enrollment of the first patient in Phase 1 Clinical Trial of DGX-001 (ZZ2103) SAN FRANCISCO, March ... WebSenior Scientist at PTC Therapeutics, Inc. Kendall Park, New Jersey, United States. 316 followers 309 connections. Join to view profile PTC … ear pain and anxiety
DIGESTOME THERAPEUTICS, INC. in Cambridge, MA - Bizapedia
WebJun 1, 2024 · Digestome Therapeutics. Digestome Therapeutics was established by Remiges Ventures, based on the ground-breaking research of Dr. Kousaku Ohinata from Kyoto University. Food affects mood, so Dr. Ohinata was inspired to identify active pharmaceutical ingredients that had origins in proteins from food sources. His well … WebPrior to joining Remiges Ventures, Taka run TK Venture Partners, Inc., which served as a consultant in charge of finance and investments for biotech and business groups including Remiges Ventures. For Remiges Ventures’ first fund, he has been on the board and Interim President of Digestome Therapeutics, Inc. and other newco projects in the ... WebDigestome Therapeutics, a biotech company developing first-in-class therapeutics that stimulate the central nervous system (CNS) via the gut-brain-axis, announced today the completion of an exclusive out-licensing … ear pain and air travel